Younis, Samaira
Hougaard, Anders
Christensen, Casper Emil
Vestergaard, Mark Bitsch
Petersen, Esben Thade
Paulson, Olaf Bjarne
Larsson, Henrik Bo Wiberg
Ashina, Messoud
Funding for this research was provided by:
Lundbeckfonden (R155-2014-171)
Research Foundation of Rigshospitalet (E-23327-02)
Article History
Received: 12 April 2018
Accepted: 7 June 2018
First Online: 18 June 2018
Ethics approval and consent to participate
: The study was approved by the Danish National Committee on Health Research Ethics (H-15019063) and conducted according to the Declaration of Helsinki and to the regulations of the Danish Data Protection Agency. The study is registered at ClincalTrials.gov (NCT03143465). Written informed consent was obtained from all participants after detailed oral and written study information.
: Not applicable.
: MA reports personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Alder, Eli Lilly, Novartis and Teva. MA participated in clinical trials as the principal investigator for Alder ALD403-CLIN-011 (Phase 3b), Amgen 20,120,178 (Phase 2), 20,120,295 (Phase 2), 20,130,255 (OLE), 20,120,297 (Phase 3), GM-11 gamma-Core-R trials, Novartis CAMG334a2301 (Phase 3b), Amgen PAC1 20,150,308 (Phase 2a), Teva TV48125-CNS-30068 (Phase 3). MA has no ownership interest and does not own stocks of any pharmaceutical company. MA serves as associated editor of Cephalalgia, co-editor of the Journal of Headache and Pain. MA is President-elect of the International Headache Society and General Secretary of the European Headache Federation. The remaining authors report no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.